Search clinical trials for: DS-8201a (DP)

Total 555 results

Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Completed

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Advanced Solid Tumors

United States, Japan
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
AstraZeneca

Completed

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Neoplasm, Breast | Adenocarcinoma, Gastric

Taiwan
Daiichi Sankyo Co., Ltd.
AstraZeneca

Completed

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Malignant Neoplasm of Breast

Japan
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer

Breast Cancer

China
Daiichi Sankyo

Active, not recruiting

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Advanced Solid Tumor

United States, China, Japan, Italy

This is a preview

Log in or create a free account to see all matching trials and use the full search.

Log in Register

Subscribe